Global Opioid Tolerance Treatment Market

Opioid Tolerance Treatment Comprehensive Study by Opioid Tolerance (Innate Tolerance, Acquired Tolerance), Route of Administration (Enteral, Parenteral, Others), Drug Analysis (NMDA Antagonists, Alpha2-adrenoceptor Agonists, Others), End-user (Hospitals & ASCs, Rehabilitation Centers, Others) Players and Region - Global Market Outlook to 2027

Opioid Tolerance Treatment Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 4.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Opioid Tolerance Treatment Market?

Opioids are defined as drugs which act on the nervous system in order to relieve pain. It is the most widely prescribed medications to treat moderate to severe chronic pain. In addition, it is widely used to manage pain in cancer patients and to treat severe constant pain in patients who suffer from terminal illnesses. Opioid tolerant patients can also be treated with additional treatment options for opioid tolerance, for instance, alpha2-adrenoceptor agonists, NMDA antagonists, among others. In October 2018, according to an article published by centers for disease control, more than 191.2 million opioid prescriptions were dispensed in the United States alone in 2017. Hence, an increasing number of opioids patients and rise in disposable income and surge in the global geriatric population are some of the major factors which are affecting the growth of the market in the future.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledBoehringer Ingelheim International GmbH (Germany), GlaxoSmithKline Plc. (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (United States), Otsuka Pharmaceutical Co., Ltd., (Japan), Johnson & Johnson Services, (United States), Aurobindo Pharma (India), Pfizer Inc., (United States), Acorda Therapeutics, Inc., (United States) and Zydus Cadila (India)
CAGR4.2%


The market study is being classified and major geographies with country level break-up. According to AMA, the Global Opioid Tolerance Treatment market is expected to see steady growth rate and may see market size of USD2197.6 Million by 2027.

Boehringer Ingelheim International GmbH (Germany), GlaxoSmithKline Plc. (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (United States), Otsuka Pharmaceutical Co., Ltd., (Japan), Johnson & Johnson Services, (United States), Aurobindo Pharma (India), Pfizer Inc., (United States), Acorda Therapeutics, Inc., (United States) and Zydus Cadila (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Boehringer Ingelheim International GmbH (Germany) and GlaxoSmithKline plc. (United Kingdom).

The market is fragmented with numerous players focusing on technique and quality of the product due to which the global opioid tolerance treatment market can witness an upsurge in the forecast period. Some of the key strategies followed by the players operating in the global opioid tolerance treatment market were innovation, product development, acquisition, and expansion. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Opioid Tolerance Treatment market throughout the forecasted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Opioid Tolerance Treatment market by Type, Application and Region.

On the basis of geography, the market of Opioid Tolerance Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2021. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rise in Opioid Consumption Worldwide For Medical and Non-Medical Purpose
  • Large Number of Opioid Prescription Dispensed For Therapeutic Purposes
  • Increasing Prevalence of Diseases that cause chronic pain, such as Cancer, Postsurgical Pain, Lower Back Pain, Fibromyalgia, and Arthritis.

Market Trend
  • Growth in the Incidence of Orthopaedic Diseases & Chronic Pain

Restraints
  • Strictly regulated by the Food and Drug Administration owing to a substantial number of drug-abuse deaths registered

Opportunities
  • Mounting Demand from Emerging Economic such as China, India, Cambodia, among others

Challenges
  • Lack of Awareness of Opioid Tolerance Treatment


In April 2019, according to an article published by the Food and Drug Administration, retail pharmacies dispensed more than 191 million opioid prescriptions to nearly 60 million patients in 2017. Hence, this will, in turn, propel the growth of opioid tolerance treatment market.


Key Target Audience
Opioid Tolerance Treatment Manufacturers Companies, Regulatory bodies, Intermediary suppliers and End Users

Report Objectives / Segmentation Covered

By Opioid Tolerance
  • Innate Tolerance
  • Acquired Tolerance

By Route of Administration
  • Enteral
  • Parenteral
  • Others

By Drug Analysis
  • NMDA Antagonists
  • Alpha2-adrenoceptor Agonists
  • Others

By End-user
  • Hospitals & ASCs
  • Rehabilitation Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Opioid Consumption Worldwide For Medical and Non-Medical Purpose
      • 3.2.2. Large Number of Opioid Prescription Dispensed For Therapeutic Purposes
      • 3.2.3. Increasing Prevalence of Diseases that cause chronic pain, such as Cancer, Postsurgical Pain, Lower Back Pain, Fibromyalgia, and Arthritis.
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness of Opioid Tolerance Treatment
    • 3.4. Market Trends
      • 3.4.1. Growth in the Incidence of Orthopaedic Diseases & Chronic Pain
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Opioid Tolerance Treatment, by Opioid Tolerance, Route of Administration, Drug Analysis, End-user and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Opioid Tolerance Treatment (Value)
      • 5.2.1. Global Opioid Tolerance Treatment by: Opioid Tolerance (Value)
        • 5.2.1.1. Innate Tolerance
        • 5.2.1.2. Acquired Tolerance
      • 5.2.2. Global Opioid Tolerance Treatment by: Route of Administration (Value)
        • 5.2.2.1. Enteral
        • 5.2.2.2. Parenteral
        • 5.2.2.3. Others
      • 5.2.3. Global Opioid Tolerance Treatment by: Drug Analysis (Value)
        • 5.2.3.1. NMDA Antagonists
        • 5.2.3.2. Alpha2-adrenoceptor Agonists
        • 5.2.3.3. Others
      • 5.2.4. Global Opioid Tolerance Treatment by: End-user (Value)
        • 5.2.4.1. Hospitals & ASCs
        • 5.2.4.2. Rehabilitation Centers
        • 5.2.4.3. Others
      • 5.2.5. Global Opioid Tolerance Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Opioid Tolerance Treatment (Volume)
      • 5.3.1. Global Opioid Tolerance Treatment by: Opioid Tolerance (Volume)
        • 5.3.1.1. Innate Tolerance
        • 5.3.1.2. Acquired Tolerance
      • 5.3.2. Global Opioid Tolerance Treatment by: Route of Administration (Volume)
        • 5.3.2.1. Enteral
        • 5.3.2.2. Parenteral
        • 5.3.2.3. Others
      • 5.3.3. Global Opioid Tolerance Treatment by: Drug Analysis (Volume)
        • 5.3.3.1. NMDA Antagonists
        • 5.3.3.2. Alpha2-adrenoceptor Agonists
        • 5.3.3.3. Others
      • 5.3.4. Global Opioid Tolerance Treatment by: End-user (Volume)
        • 5.3.4.1. Hospitals & ASCs
        • 5.3.4.2. Rehabilitation Centers
        • 5.3.4.3. Others
      • 5.3.5. Global Opioid Tolerance Treatment Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Opioid Tolerance Treatment (Price)
  • 6. Opioid Tolerance Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boehringer Ingelheim International GmbH (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan N.V. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Otsuka Pharmaceutical Co., Ltd., (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson Services, (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Aurobindo Pharma (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc., (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Acorda Therapeutics, Inc., (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Zydus Cadila (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Opioid Tolerance Treatment Sale, by Opioid Tolerance, Route of Administration, Drug Analysis, End-user and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Opioid Tolerance Treatment (Value)
      • 7.2.1. Global Opioid Tolerance Treatment by: Opioid Tolerance (Value)
        • 7.2.1.1. Innate Tolerance
        • 7.2.1.2. Acquired Tolerance
      • 7.2.2. Global Opioid Tolerance Treatment by: Route of Administration (Value)
        • 7.2.2.1. Enteral
        • 7.2.2.2. Parenteral
        • 7.2.2.3. Others
      • 7.2.3. Global Opioid Tolerance Treatment by: Drug Analysis (Value)
        • 7.2.3.1. NMDA Antagonists
        • 7.2.3.2. Alpha2-adrenoceptor Agonists
        • 7.2.3.3. Others
      • 7.2.4. Global Opioid Tolerance Treatment by: End-user (Value)
        • 7.2.4.1. Hospitals & ASCs
        • 7.2.4.2. Rehabilitation Centers
        • 7.2.4.3. Others
      • 7.2.5. Global Opioid Tolerance Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Opioid Tolerance Treatment (Volume)
      • 7.3.1. Global Opioid Tolerance Treatment by: Opioid Tolerance (Volume)
        • 7.3.1.1. Innate Tolerance
        • 7.3.1.2. Acquired Tolerance
      • 7.3.2. Global Opioid Tolerance Treatment by: Route of Administration (Volume)
        • 7.3.2.1. Enteral
        • 7.3.2.2. Parenteral
        • 7.3.2.3. Others
      • 7.3.3. Global Opioid Tolerance Treatment by: Drug Analysis (Volume)
        • 7.3.3.1. NMDA Antagonists
        • 7.3.3.2. Alpha2-adrenoceptor Agonists
        • 7.3.3.3. Others
      • 7.3.4. Global Opioid Tolerance Treatment by: End-user (Volume)
        • 7.3.4.1. Hospitals & ASCs
        • 7.3.4.2. Rehabilitation Centers
        • 7.3.4.3. Others
      • 7.3.5. Global Opioid Tolerance Treatment Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Opioid Tolerance Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Opioid Tolerance Treatment: by Opioid Tolerance(USD Million)
  • Table 2. Opioid Tolerance Treatment Innate Tolerance , by Region USD Million (2016-2021)
  • Table 3. Opioid Tolerance Treatment Acquired Tolerance , by Region USD Million (2016-2021)
  • Table 4. Opioid Tolerance Treatment: by Route of Administration(USD Million)
  • Table 5. Opioid Tolerance Treatment Enteral , by Region USD Million (2016-2021)
  • Table 6. Opioid Tolerance Treatment Parenteral , by Region USD Million (2016-2021)
  • Table 7. Opioid Tolerance Treatment Others , by Region USD Million (2016-2021)
  • Table 8. Opioid Tolerance Treatment: by Drug Analysis(USD Million)
  • Table 9. Opioid Tolerance Treatment NMDA Antagonists , by Region USD Million (2016-2021)
  • Table 10. Opioid Tolerance Treatment Alpha2-adrenoceptor Agonists , by Region USD Million (2016-2021)
  • Table 11. Opioid Tolerance Treatment Others , by Region USD Million (2016-2021)
  • Table 12. Opioid Tolerance Treatment: by End-user(USD Million)
  • Table 13. Opioid Tolerance Treatment Hospitals & ASCs , by Region USD Million (2016-2021)
  • Table 14. Opioid Tolerance Treatment Rehabilitation Centers , by Region USD Million (2016-2021)
  • Table 15. Opioid Tolerance Treatment Others , by Region USD Million (2016-2021)
  • Table 16. South America Opioid Tolerance Treatment, by Country USD Million (2016-2021)
  • Table 17. South America Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 18. South America Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 19. South America Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 20. South America Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 21. Brazil Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 22. Brazil Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 23. Brazil Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 24. Brazil Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 25. Argentina Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 26. Argentina Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 27. Argentina Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 28. Argentina Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 29. Rest of South America Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 30. Rest of South America Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 31. Rest of South America Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 32. Rest of South America Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 33. Asia Pacific Opioid Tolerance Treatment, by Country USD Million (2016-2021)
  • Table 34. Asia Pacific Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 35. Asia Pacific Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 36. Asia Pacific Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 37. Asia Pacific Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 38. China Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 39. China Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 40. China Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 41. China Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 42. Japan Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 43. Japan Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 44. Japan Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 45. Japan Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 46. India Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 47. India Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 48. India Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 49. India Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 50. South Korea Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 51. South Korea Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 52. South Korea Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 53. South Korea Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 54. Taiwan Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 55. Taiwan Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 56. Taiwan Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 57. Taiwan Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 58. Australia Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 59. Australia Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 60. Australia Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 61. Australia Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 66. Europe Opioid Tolerance Treatment, by Country USD Million (2016-2021)
  • Table 67. Europe Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 68. Europe Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 69. Europe Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 70. Europe Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 71. Germany Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 72. Germany Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 73. Germany Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 74. Germany Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 75. France Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 76. France Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 77. France Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 78. France Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 79. Italy Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 80. Italy Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 81. Italy Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 82. Italy Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 83. United Kingdom Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 84. United Kingdom Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 85. United Kingdom Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 86. United Kingdom Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 87. Netherlands Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 88. Netherlands Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 89. Netherlands Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 90. Netherlands Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 91. Rest of Europe Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 92. Rest of Europe Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 93. Rest of Europe Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 94. Rest of Europe Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 95. MEA Opioid Tolerance Treatment, by Country USD Million (2016-2021)
  • Table 96. MEA Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 97. MEA Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 98. MEA Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 99. MEA Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 100. Middle East Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 101. Middle East Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 102. Middle East Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 103. Middle East Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 104. Africa Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 105. Africa Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 106. Africa Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 107. Africa Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 108. North America Opioid Tolerance Treatment, by Country USD Million (2016-2021)
  • Table 109. North America Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 110. North America Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 111. North America Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 112. North America Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 113. United States Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 114. United States Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 115. United States Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 116. United States Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 117. Canada Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 118. Canada Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 119. Canada Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 120. Canada Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 121. Mexico Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2016-2021)
  • Table 122. Mexico Opioid Tolerance Treatment, by Route of Administration USD Million (2016-2021)
  • Table 123. Mexico Opioid Tolerance Treatment, by Drug Analysis USD Million (2016-2021)
  • Table 124. Mexico Opioid Tolerance Treatment, by End-user USD Million (2016-2021)
  • Table 125. Opioid Tolerance Treatment Sales: by Opioid Tolerance(M Tons)
  • Table 126. Opioid Tolerance Treatment Sales Innate Tolerance , by Region M Tons (2016-2021)
  • Table 127. Opioid Tolerance Treatment Sales Acquired Tolerance , by Region M Tons (2016-2021)
  • Table 128. Opioid Tolerance Treatment Sales: by Route of Administration(M Tons)
  • Table 129. Opioid Tolerance Treatment Sales Enteral , by Region M Tons (2016-2021)
  • Table 130. Opioid Tolerance Treatment Sales Parenteral , by Region M Tons (2016-2021)
  • Table 131. Opioid Tolerance Treatment Sales Others , by Region M Tons (2016-2021)
  • Table 132. Opioid Tolerance Treatment Sales: by Drug Analysis(M Tons)
  • Table 133. Opioid Tolerance Treatment Sales NMDA Antagonists , by Region M Tons (2016-2021)
  • Table 134. Opioid Tolerance Treatment Sales Alpha2-adrenoceptor Agonists , by Region M Tons (2016-2021)
  • Table 135. Opioid Tolerance Treatment Sales Others , by Region M Tons (2016-2021)
  • Table 136. Opioid Tolerance Treatment Sales: by End-user(M Tons)
  • Table 137. Opioid Tolerance Treatment Sales Hospitals & ASCs , by Region M Tons (2016-2021)
  • Table 138. Opioid Tolerance Treatment Sales Rehabilitation Centers , by Region M Tons (2016-2021)
  • Table 139. Opioid Tolerance Treatment Sales Others , by Region M Tons (2016-2021)
  • Table 140. South America Opioid Tolerance Treatment Sales, by Country M Tons (2016-2021)
  • Table 141. South America Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 142. South America Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 143. South America Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 144. South America Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 145. Brazil Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 146. Brazil Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 147. Brazil Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 148. Brazil Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 149. Argentina Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 150. Argentina Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 151. Argentina Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 152. Argentina Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 153. Rest of South America Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 154. Rest of South America Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 155. Rest of South America Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 156. Rest of South America Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 157. Asia Pacific Opioid Tolerance Treatment Sales, by Country M Tons (2016-2021)
  • Table 158. Asia Pacific Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 159. Asia Pacific Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 160. Asia Pacific Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 161. Asia Pacific Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 162. China Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 163. China Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 164. China Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 165. China Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 166. Japan Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 167. Japan Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 168. Japan Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 169. Japan Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 170. India Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 171. India Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 172. India Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 173. India Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 174. South Korea Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 175. South Korea Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 176. South Korea Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 177. South Korea Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 178. Taiwan Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 179. Taiwan Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 180. Taiwan Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 181. Taiwan Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 182. Australia Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 183. Australia Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 184. Australia Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 185. Australia Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 186. Rest of Asia-Pacific Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 187. Rest of Asia-Pacific Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 188. Rest of Asia-Pacific Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 189. Rest of Asia-Pacific Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 190. Europe Opioid Tolerance Treatment Sales, by Country M Tons (2016-2021)
  • Table 191. Europe Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 192. Europe Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 193. Europe Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 194. Europe Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 195. Germany Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 196. Germany Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 197. Germany Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 198. Germany Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 199. France Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 200. France Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 201. France Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 202. France Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 203. Italy Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 204. Italy Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 205. Italy Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 206. Italy Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 207. United Kingdom Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 208. United Kingdom Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 209. United Kingdom Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 210. United Kingdom Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 211. Netherlands Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 212. Netherlands Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 213. Netherlands Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 214. Netherlands Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 215. Rest of Europe Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 216. Rest of Europe Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 217. Rest of Europe Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 218. Rest of Europe Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 219. MEA Opioid Tolerance Treatment Sales, by Country M Tons (2016-2021)
  • Table 220. MEA Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 221. MEA Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 222. MEA Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 223. MEA Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 224. Middle East Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 225. Middle East Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 226. Middle East Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 227. Middle East Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 228. Africa Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 229. Africa Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 230. Africa Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 231. Africa Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 232. North America Opioid Tolerance Treatment Sales, by Country M Tons (2016-2021)
  • Table 233. North America Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 234. North America Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 235. North America Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 236. North America Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 237. United States Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 238. United States Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 239. United States Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 240. United States Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 241. Canada Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 242. Canada Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 243. Canada Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 244. Canada Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 245. Mexico Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2016-2021)
  • Table 246. Mexico Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2016-2021)
  • Table 247. Mexico Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2016-2021)
  • Table 248. Mexico Opioid Tolerance Treatment Sales, by End-user M Tons (2016-2021)
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Opioid Tolerance Treatment: by Opioid Tolerance(USD Million)
  • Table 260. Opioid Tolerance Treatment Innate Tolerance , by Region USD Million (2022-2027)
  • Table 261. Opioid Tolerance Treatment Acquired Tolerance , by Region USD Million (2022-2027)
  • Table 262. Opioid Tolerance Treatment: by Route of Administration(USD Million)
  • Table 263. Opioid Tolerance Treatment Enteral , by Region USD Million (2022-2027)
  • Table 264. Opioid Tolerance Treatment Parenteral , by Region USD Million (2022-2027)
  • Table 265. Opioid Tolerance Treatment Others , by Region USD Million (2022-2027)
  • Table 266. Opioid Tolerance Treatment: by Drug Analysis(USD Million)
  • Table 267. Opioid Tolerance Treatment NMDA Antagonists , by Region USD Million (2022-2027)
  • Table 268. Opioid Tolerance Treatment Alpha2-adrenoceptor Agonists , by Region USD Million (2022-2027)
  • Table 269. Opioid Tolerance Treatment Others , by Region USD Million (2022-2027)
  • Table 270. Opioid Tolerance Treatment: by End-user(USD Million)
  • Table 271. Opioid Tolerance Treatment Hospitals & ASCs , by Region USD Million (2022-2027)
  • Table 272. Opioid Tolerance Treatment Rehabilitation Centers , by Region USD Million (2022-2027)
  • Table 273. Opioid Tolerance Treatment Others , by Region USD Million (2022-2027)
  • Table 274. South America Opioid Tolerance Treatment, by Country USD Million (2022-2027)
  • Table 275. South America Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 276. South America Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 277. South America Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 278. South America Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 279. Brazil Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 280. Brazil Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 281. Brazil Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 282. Brazil Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 283. Argentina Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 284. Argentina Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 285. Argentina Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 286. Argentina Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 287. Rest of South America Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 288. Rest of South America Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 289. Rest of South America Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 290. Rest of South America Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 291. Asia Pacific Opioid Tolerance Treatment, by Country USD Million (2022-2027)
  • Table 292. Asia Pacific Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 293. Asia Pacific Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 294. Asia Pacific Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 295. Asia Pacific Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 296. China Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 297. China Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 298. China Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 299. China Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 300. Japan Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 301. Japan Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 302. Japan Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 303. Japan Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 304. India Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 305. India Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 306. India Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 307. India Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 308. South Korea Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 309. South Korea Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 310. South Korea Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 311. South Korea Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 312. Taiwan Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 313. Taiwan Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 314. Taiwan Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 315. Taiwan Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 316. Australia Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 317. Australia Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 318. Australia Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 319. Australia Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 320. Rest of Asia-Pacific Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 321. Rest of Asia-Pacific Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 322. Rest of Asia-Pacific Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 323. Rest of Asia-Pacific Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 324. Europe Opioid Tolerance Treatment, by Country USD Million (2022-2027)
  • Table 325. Europe Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 326. Europe Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 327. Europe Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 328. Europe Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 329. Germany Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 330. Germany Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 331. Germany Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 332. Germany Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 333. France Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 334. France Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 335. France Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 336. France Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 337. Italy Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 338. Italy Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 339. Italy Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 340. Italy Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 341. United Kingdom Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 342. United Kingdom Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 343. United Kingdom Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 344. United Kingdom Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 345. Netherlands Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 346. Netherlands Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 347. Netherlands Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 348. Netherlands Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 349. Rest of Europe Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 350. Rest of Europe Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 351. Rest of Europe Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 352. Rest of Europe Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 353. MEA Opioid Tolerance Treatment, by Country USD Million (2022-2027)
  • Table 354. MEA Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 355. MEA Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 356. MEA Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 357. MEA Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 358. Middle East Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 359. Middle East Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 360. Middle East Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 361. Middle East Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 362. Africa Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 363. Africa Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 364. Africa Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 365. Africa Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 366. North America Opioid Tolerance Treatment, by Country USD Million (2022-2027)
  • Table 367. North America Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 368. North America Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 369. North America Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 370. North America Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 371. United States Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 372. United States Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 373. United States Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 374. United States Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 375. Canada Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 376. Canada Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 377. Canada Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 378. Canada Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 379. Mexico Opioid Tolerance Treatment, by Opioid Tolerance USD Million (2022-2027)
  • Table 380. Mexico Opioid Tolerance Treatment, by Route of Administration USD Million (2022-2027)
  • Table 381. Mexico Opioid Tolerance Treatment, by Drug Analysis USD Million (2022-2027)
  • Table 382. Mexico Opioid Tolerance Treatment, by End-user USD Million (2022-2027)
  • Table 383. Opioid Tolerance Treatment Sales: by Opioid Tolerance(M Tons)
  • Table 384. Opioid Tolerance Treatment Sales Innate Tolerance , by Region M Tons (2022-2027)
  • Table 385. Opioid Tolerance Treatment Sales Acquired Tolerance , by Region M Tons (2022-2027)
  • Table 386. Opioid Tolerance Treatment Sales: by Route of Administration(M Tons)
  • Table 387. Opioid Tolerance Treatment Sales Enteral , by Region M Tons (2022-2027)
  • Table 388. Opioid Tolerance Treatment Sales Parenteral , by Region M Tons (2022-2027)
  • Table 389. Opioid Tolerance Treatment Sales Others , by Region M Tons (2022-2027)
  • Table 390. Opioid Tolerance Treatment Sales: by Drug Analysis(M Tons)
  • Table 391. Opioid Tolerance Treatment Sales NMDA Antagonists , by Region M Tons (2022-2027)
  • Table 392. Opioid Tolerance Treatment Sales Alpha2-adrenoceptor Agonists , by Region M Tons (2022-2027)
  • Table 393. Opioid Tolerance Treatment Sales Others , by Region M Tons (2022-2027)
  • Table 394. Opioid Tolerance Treatment Sales: by End-user(M Tons)
  • Table 395. Opioid Tolerance Treatment Sales Hospitals & ASCs , by Region M Tons (2022-2027)
  • Table 396. Opioid Tolerance Treatment Sales Rehabilitation Centers , by Region M Tons (2022-2027)
  • Table 397. Opioid Tolerance Treatment Sales Others , by Region M Tons (2022-2027)
  • Table 398. South America Opioid Tolerance Treatment Sales, by Country M Tons (2022-2027)
  • Table 399. South America Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 400. South America Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 401. South America Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 402. South America Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 403. Brazil Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 404. Brazil Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 405. Brazil Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 406. Brazil Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 407. Argentina Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 408. Argentina Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 409. Argentina Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 410. Argentina Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 411. Rest of South America Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 412. Rest of South America Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 413. Rest of South America Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 414. Rest of South America Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 415. Asia Pacific Opioid Tolerance Treatment Sales, by Country M Tons (2022-2027)
  • Table 416. Asia Pacific Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 417. Asia Pacific Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 418. Asia Pacific Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 419. Asia Pacific Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 420. China Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 421. China Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 422. China Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 423. China Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 424. Japan Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 425. Japan Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 426. Japan Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 427. Japan Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 428. India Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 429. India Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 430. India Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 431. India Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 432. South Korea Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 433. South Korea Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 434. South Korea Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 435. South Korea Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 436. Taiwan Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 437. Taiwan Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 438. Taiwan Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 439. Taiwan Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 440. Australia Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 441. Australia Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 442. Australia Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 443. Australia Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 444. Rest of Asia-Pacific Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 445. Rest of Asia-Pacific Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 446. Rest of Asia-Pacific Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 447. Rest of Asia-Pacific Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 448. Europe Opioid Tolerance Treatment Sales, by Country M Tons (2022-2027)
  • Table 449. Europe Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 450. Europe Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 451. Europe Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 452. Europe Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 453. Germany Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 454. Germany Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 455. Germany Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 456. Germany Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 457. France Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 458. France Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 459. France Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 460. France Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 461. Italy Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 462. Italy Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 463. Italy Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 464. Italy Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 465. United Kingdom Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 466. United Kingdom Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 467. United Kingdom Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 468. United Kingdom Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 469. Netherlands Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 470. Netherlands Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 471. Netherlands Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 472. Netherlands Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 473. Rest of Europe Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 474. Rest of Europe Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 475. Rest of Europe Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 476. Rest of Europe Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 477. MEA Opioid Tolerance Treatment Sales, by Country M Tons (2022-2027)
  • Table 478. MEA Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 479. MEA Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 480. MEA Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 481. MEA Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 482. Middle East Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 483. Middle East Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 484. Middle East Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 485. Middle East Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 486. Africa Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 487. Africa Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 488. Africa Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 489. Africa Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 490. North America Opioid Tolerance Treatment Sales, by Country M Tons (2022-2027)
  • Table 491. North America Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 492. North America Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 493. North America Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 494. North America Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 495. United States Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 496. United States Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 497. United States Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 498. United States Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 499. Canada Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 500. Canada Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 501. Canada Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 502. Canada Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 503. Mexico Opioid Tolerance Treatment Sales, by Opioid Tolerance M Tons (2022-2027)
  • Table 504. Mexico Opioid Tolerance Treatment Sales, by Route of Administration M Tons (2022-2027)
  • Table 505. Mexico Opioid Tolerance Treatment Sales, by Drug Analysis M Tons (2022-2027)
  • Table 506. Mexico Opioid Tolerance Treatment Sales, by End-user M Tons (2022-2027)
  • Table 507. Research Programs/Design for This Report
  • Table 508. Key Data Information from Secondary Sources
  • Table 509. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Opioid Tolerance Treatment: by Opioid Tolerance USD Million (2016-2021)
  • Figure 5. Global Opioid Tolerance Treatment: by Route of Administration USD Million (2016-2021)
  • Figure 6. Global Opioid Tolerance Treatment: by Drug Analysis USD Million (2016-2021)
  • Figure 7. Global Opioid Tolerance Treatment: by End-user USD Million (2016-2021)
  • Figure 8. South America Opioid Tolerance Treatment Share (%), by Country
  • Figure 9. Asia Pacific Opioid Tolerance Treatment Share (%), by Country
  • Figure 10. Europe Opioid Tolerance Treatment Share (%), by Country
  • Figure 11. MEA Opioid Tolerance Treatment Share (%), by Country
  • Figure 12. North America Opioid Tolerance Treatment Share (%), by Country
  • Figure 13. Global Opioid Tolerance Treatment: by Opioid Tolerance M Tons (2016-2021)
  • Figure 14. Global Opioid Tolerance Treatment: by Route of Administration M Tons (2016-2021)
  • Figure 15. Global Opioid Tolerance Treatment: by Drug Analysis M Tons (2016-2021)
  • Figure 16. Global Opioid Tolerance Treatment: by End-user M Tons (2016-2021)
  • Figure 17. South America Opioid Tolerance Treatment Share (%), by Country
  • Figure 18. Asia Pacific Opioid Tolerance Treatment Share (%), by Country
  • Figure 19. Europe Opioid Tolerance Treatment Share (%), by Country
  • Figure 20. MEA Opioid Tolerance Treatment Share (%), by Country
  • Figure 21. North America Opioid Tolerance Treatment Share (%), by Country
  • Figure 22. Global Opioid Tolerance Treatment share by Players 2021 (%)
  • Figure 23. Global Opioid Tolerance Treatment share by Players (Top 3) 2021(%)
  • Figure 24. Global Opioid Tolerance Treatment share by Players (Top 5) 2021(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Boehringer Ingelheim International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Boehringer Ingelheim International GmbH (Germany) Revenue: by Geography 2021
  • Figure 28. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2021
  • Figure 30. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 31. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2021
  • Figure 32. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Mylan N.V. (United States) Revenue: by Geography 2021
  • Figure 34. Otsuka Pharmaceutical Co., Ltd., (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Otsuka Pharmaceutical Co., Ltd., (Japan) Revenue: by Geography 2021
  • Figure 36. Johnson & Johnson Services, (United States) Revenue, Net Income and Gross profit
  • Figure 37. Johnson & Johnson Services, (United States) Revenue: by Geography 2021
  • Figure 38. Aurobindo Pharma (India) Revenue, Net Income and Gross profit
  • Figure 39. Aurobindo Pharma (India) Revenue: by Geography 2021
  • Figure 40. Pfizer Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 41. Pfizer Inc., (United States) Revenue: by Geography 2021
  • Figure 42. Acorda Therapeutics, Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 43. Acorda Therapeutics, Inc., (United States) Revenue: by Geography 2021
  • Figure 44. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 45. Zydus Cadila (India) Revenue: by Geography 2021
  • Figure 46. Global Opioid Tolerance Treatment: by Opioid Tolerance USD Million (2022-2027)
  • Figure 47. Global Opioid Tolerance Treatment: by Route of Administration USD Million (2022-2027)
  • Figure 48. Global Opioid Tolerance Treatment: by Drug Analysis USD Million (2022-2027)
  • Figure 49. Global Opioid Tolerance Treatment: by End-user USD Million (2022-2027)
  • Figure 50. South America Opioid Tolerance Treatment Share (%), by Country
  • Figure 51. Asia Pacific Opioid Tolerance Treatment Share (%), by Country
  • Figure 52. Europe Opioid Tolerance Treatment Share (%), by Country
  • Figure 53. MEA Opioid Tolerance Treatment Share (%), by Country
  • Figure 54. North America Opioid Tolerance Treatment Share (%), by Country
  • Figure 55. Global Opioid Tolerance Treatment: by Opioid Tolerance M Tons (2022-2027)
  • Figure 56. Global Opioid Tolerance Treatment: by Route of Administration M Tons (2022-2027)
  • Figure 57. Global Opioid Tolerance Treatment: by Drug Analysis M Tons (2022-2027)
  • Figure 58. Global Opioid Tolerance Treatment: by End-user M Tons (2022-2027)
  • Figure 59. South America Opioid Tolerance Treatment Share (%), by Country
  • Figure 60. Asia Pacific Opioid Tolerance Treatment Share (%), by Country
  • Figure 61. Europe Opioid Tolerance Treatment Share (%), by Country
  • Figure 62. MEA Opioid Tolerance Treatment Share (%), by Country
  • Figure 63. North America Opioid Tolerance Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Boehringer Ingelheim International GmbH (Germany)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Mylan N.V. (United States)
  • Otsuka Pharmaceutical Co., Ltd., (Japan)
  • Johnson & Johnson Services, (United States)
  • Aurobindo Pharma (India)
  • Pfizer Inc., (United States)
  • Acorda Therapeutics, Inc., (United States)
  • Zydus Cadila (India)
Additional players considered in the study are as follows:
Boehringer Ingelheim International GmbH (Germany) , GlaxoSmithKline plc. (United Kingdom)
Select User Access Type

Key Highlights of Report


May 2022 235 Pages 93 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Opioid Tolerance Treatment Market Quantitative research analysis
Global Opioid Tolerance Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rise in Opioid Consumption Worldwide For Medical and Non-Medical Purpose " is seen as one of major growth factors of Opioid Tolerance Treatment Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Opioid Tolerance Treatment Market in coming years.

Know More About Global Opioid Tolerance Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Glial Cell Line Derived Neurotrophic Factor Comprehensive Study by Type (GSK-812, LAUR-301, TW-002, AMT-090, Other), Application (Amyotrophic Lateral Sclerosis, Brain Ischemia, Parkinson’s Disease, R...
$ 3350
Expressed Competent Cells Comprehensive Study by Type (Chemically Competent Cells, Electro-Competent Cells), Application (Plasmid DNA, Bacterial Transformation, Cloning), Method (Natural Competence, ...
$ 3800
Plate Spreader Comprehensive Study by Type (Biochemical analysis, Biology lab equipment, Blood analysis system, Others), Application (Hospitals, Clinics, Laboratories), Usage Form (Cell holder, Bacte...
$ 3650
Partial Knee Replacement (PKR) Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Others), Implant (Fixed-Bearing Implants, Mobile-Bearing Implants, Media...
$ 3800
Biosimilars Treatment Comprehensive Study by Type (Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor (Filgrastim), Insulin, Interfe...
$ 3750
Medicated Health Product Comprehensive Study by Type (Herbal Supplements, Hand Sanitizers, Body Powders, Pain Reliefs, Oral Health Products, Antiperspirant, Deodorant, Others), Sales Channel (Online,...
$ 3450